Simple research view

GILD · Gilead Sciences, Inc.

$144.81 -0.58% Sep 10 close

Detected setup Trend Only · Setup Score 70/100

Stand aside — setup invalidated

Setup score 70, but distribution days reach 5 or more — stand aside until the condition resets.

Ask about GILD

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$GILD

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a large-cap Biotechnology company in the Health Technology sector with a market cap of $180B.

Health Technology Biotechnology stock Stage 2 · Advancing Base 1

$144.81 latest close

Join to Watchlist $GILD Share card

Verdict · setup score 70/100 · data Sep 10 close · 1 session old

Stand aside — setup invalidated

Setup score 70, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart

Earnings

Normal technical setup

No sourced report date Event risk is not modelled for this symbol

Deterministic evidence

GILD-0.58%

Sector proxy · XLV-0.55%

Broad market · SPY-0.60%

Same completed session window ending 2026-09-10. GILD was -0.03 points vs XLV. +0.02 points vs SPY.

Session internals Mixed

Rule: direction and internals disagree — it met neither the strong nor the weak rule. Judged on internals, not on the size of the move.

Vs prior close-0.58% From the open-0.27% Range position51% GapNo gap

QQQ confirmationConfirming (-1.06%) SMH confirmationConfirming (-2.44%)

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $144.81 -0.6% Sep 10 close

52W High $157.29 7.9% below high

Wks Since High 29w

Base Depth 22.0% 22.8% today

RS Rank 31 percentile of scan

SMA 50 $137.74

Avg Vol 6,341,648

Rel Vol (Sep 10) 0.95×

More stats

52W Low $108.46

Tight Wks 0

Base B1

SMA 200 $134.65

RS Line vs High -16.0%

RS Line Slope +7.6% ▲

Group Rank #15/58

ADR% 2.2%

ATR(14) $3.38 (2.3%)

Vol Pace (live) N/A

U/D Vol 3.81

A/D Days 16A / 19D

A/D Rating E

VDU Bars 0/10 d

Position in 52-week range 74thpercentile of the 52-week range

$108.46low

$157.29high

GILD Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for GILD.

Create Free Account

Technical Analysis Report Card

$GILD · $144.81 · as of 2026-09-10 · multi-factor read

/ 100

Technicals 79/100

Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating

Weekly ▲ Uptrend

Monthly ▲ Uptrend

Moving Averages

50-day$137.74 ↑

100-day$133.79 ↑

200-day$134.65 ↑

Golden Cross (fresh)

RSI (14)

Reading52.8 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateWeakening

Histogram-0.685

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width43% · 10.7%

Mid-band — no directional band edge in play.

Volume · Buyer vs Seller

Up/Down vol3.81 · Accumulation

Rel volume0.95×

Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is easing versus its baseline.

Support & Resistance

R · $149.38swing level

R · $152.55swing level

R · $157.2952-week high

Price · $144.81now

S · $143.06swing level

S · $133.89swing level

S · $128.49swing level

Fibonacci · Uptrend swing

23.6% ◄ price here$145.20

38.2%$140.65

50.0%$136.97

61.8%$133.29

78.6%$128.06

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for GILD — plus the full 500+ symbol scanner and Ask-the-Legends chat.

Start your 7-day free trial →

Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishVolume accumulation

Want this read in a legend's voice? Ask a Legend about GILD

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini C

Trend-template read: 6/10 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $144.81, MA150 $137.36, MA200 $134.65

1.2 150-day MA > 200-day MAMA150 $137.36 vs MA200 $134.65

Failing evidence

1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 40

2. Quarterly EPS growth ≥ 25%From SEPA scan

6/10 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

N: Near 52-week high or RS line new high7.9% below high | RS line new high: False

S: Base tightness (ATR% ≤ 4.5%)ATR% 2.33%

Failing evidence

L: RS rank ≥ 80 (IBD leadership)RS rank 40

C: Quarterly EPS acceleration ≥ 25%Data unavailable

2/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein C

Stage-analysis read: Stage 2 is present; 3 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $144.81 vs MA200 $134.65

Failing evidence

Volume expansion above averageVolume ratio 0.95x

Relative strength ≥ 60RS 40

4/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$144.81

Distance from 52-week high7.9% below high

Failing evidence

Relative strengthRS 40

Volume vs average0.95x

3/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$144.81

Distance from 52-week high7.9% below high

Failing evidence

Relative strengthRS 40

Volume vs average0.95x

3/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$144.81

Distance from 52-week high7.9% below high

Failing evidence

Relative strengthRS 40

Volume vs average0.95x

3/6 checks

Method → Playbook → Ask →

Base & Breakout

Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +0 E

Minervini · Grade Card

Fundamentals & leadership quality — Minervini’s published criteria · 2/7 met

C 2/7 criteria

Separate score from the Minervini Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ —

✗ Revenue growth ≥20% YoY +2%

✗ Gross margin ≥30% —

✗ ROE ≥17% —

✗ RS rating ≥80 (leadership) 40

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -7.9%

Method Playbook

Trade it like Weinstein EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

Weinstein C · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.

Pivot

Pro level

Published-method rule: Use Stage 1 resistance and the rising 30-week moving average as the Stage 2 transition boundary.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a Stage 2 breakout above resistance on expanding volume; avoid entries while the 30-week average is flat or falling.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Start below the breakout structure or Stage 1 support where a return to the base invalidates the Stage 2 transition.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Trail beneath rising 30-week support or later higher swing lows while Stage 2 remains intact.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit on a decisive 30-week support failure or a Stage 3/Stage 4 transition; never treat a failed Stage 2 break as healthy consolidation.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Forming Patterns (predictive — not confirmed)

Cup & Handle bullish near confirmation

90% built

Cup complete, possible handle forming — watch for a quiet 5-15 bar drift on light volume holding above ~139.34 (mid-cup), then a breakout through ~152.55 on strong volume.

Confirms above 152.55

Invalidates at 139.34

Rim 157.29

Cup Low 121.39

Pivot 152.55

Mid Cup 139.34

Cup depth 23%, recovery 65%, handle=forming

Predictive pattern recognition is educational — most forming structures never confirm. Wait for the confirmation level before treating this as a setup.

Pattern Analysis

Trend Only

70 setup score

RS Score 40

Trend template 7/8

Why This Setup?

Trend Only · schematic

Gatekeeper 7/8 | Strong trend (7/8) | Accumulation (3.8× up/dn vol) | Stage 2

The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

1/7 universals met

A relative-strength leader — not met RS rank 31 — laggard
Risk is defined — not met No stop — undefined risk
Asymmetric reward — partly met No target set
Clear of earnings — partly met Report date unknown
Not chasing (in range) — partly met Pivot distance unknown
Volume confirms — partly met 0.9× average — light
In a confirmed uptrend — met Stage 2 · Trend template 7/8

Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $144.81 vs SMA150 $137.36 / SMA200 $134.65

SMA 150 above SMA 200 SMA150 $137.36 vs SMA200 $134.65

SMA 200 trending up Slope +2.37 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $137.74

Price above SMA 50 $144.81 vs SMA50 $137.74

30%+ above 52-week low +33.5% from $108.46

Within 25% of 52-week high -7.9% from $157.29

RS score above 70 RS 40

Fundamentals

52W Range

74%

Mkt Cap SEC

179.6B

Rev YoY

+2%

EPS TTM

$6.78

P/E TTM

21.4x

Float

1.2B

Company

Company profile

Gilead Sciences, Inc.

GILD · NASDAQ · Health Technology · Biotechnology

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

8/8

W. RS

W. Support

$121.39

W. Resist

$152.55

Weekly Structure

Trend Neutral

Tight Weeks 0

Confirmation Neutral

Scan History

20× streak

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 10

Trend Only ✓ Gate

76 0.0%

Sep 09

Trend Only ✓ Gate

73 -0.6%

Sep 09

Trend Only ✓ Gate

73 -0.6%

Get the full picture on GILD

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial